Collections

Filters ​

  • Focus |

    Cancer cell therapy has become one of the most promising approaches for cancer treatment. In recent years, progress in the underlying science, clinical application and manufacturing of cell therapies has accelerated dramatically.

    Image: Susanne Harris

  • Focus |

    Launched a decade ago, the US Food and Drug Administration's Critical Path Initiative has helped catalyse the formation of many consortia focused on drug development challenges. In this Focus, representatives from some of the major stakeholder groups and consortia describe their roles, summarize progress so far and provide their perspectives on the opportunities, challenges and lessons learned for biomedical consortia in general.

  • Focus |

    To highlight the problem of resistance to antimicrobials, Nature Reviews Microbiology presents a set of specially commissioned articles that focus on key issues in the field, including the role of antibiotic resistance in nature, how the spread of antimicrobial resistance could be limited and the pharmaceutical strategies that are used to overcome resistance to various classes of antimicrobials. The Focus issue is accompanied by a joint Web Focus with Nature Reviews Drug Discovery.

  • Focus |

    Apoptosis, the major form of controlled cell death, has a key role in the pathogenesis of diseases including cancer, inflammation and neurodegenerative disorders. The past decade has witnessed tremendous progress in understanding of the molecular mechanisms of apoptosis regulation, which has revealed a number of highly promising therapeutic targets, particularly for anticancer strategies. This focus provides a cutting-edge overview of the science and business of targeting apoptosis.

  • Focus |

    Unrelieved pain associated with conditions such as arthritis, diabetes, cancer and serious injury represents a major unmet medical need. With the aim of highlighting approaches to tackling the challenges in this field, this special collection integrates articles that discuss strategies to drive forward analgesic drug development with those that explore new targets for pain therapeutics.

  • Focus |

    This issue provides several articles focusing on antiviral therapy. Additional material, brought together in a joint focus with Nature Reviews Drug Discoverysupported by our principal sponsor Pfizer and our supporting sponsor Gilead.

  • Focus |

    A collection of articles from Nature Biotechnology, brought together in a joint focus with Nature Reviews Drug Discovery, on the science and business of antibacterial discovery and development.

  • Focus |

    For the past decade, the number of molecular targets for approved drugs has been debated. However, to develop and apply predictive methods to assess the future potential for therapeutic exploitation, the number, characteristics and biological diversity of these targets needs to be established. Here, we provide a comprehensive survey of current drug targets and drugs that modulate them.

  • Focus |

    We examine the role of kinase signalling in cancer and the potential for developing effective therapies that can modulate various kinase pathways. Following the success of targeted kinase inhibitor therapies such as imatinib and gefitinib this continues to be a fast moving area of research.

  • Focus |

    Atherothrombosis, the leading cause of morbidity and mortality. As discussed in these articles, recent progress in the understanding of the pathogenesis of atherothrombosis, and in the application of approaches to assess disease progression, has provided new impetus to the discovery and development of novel drugs for this condition.

  • Focus |

    This Focus provides a comprehensive collection of articles on the development of pharmacogenetics, covering topics ranging from the latest approaches in pharmacogenetics research to evolving regulatory frameworks and ethical issues